Yüklüyor......
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis
Sitagliptin is a dipeptidyl peptidase-4 inhibitor commonly used in the treatment of type 2 diabetes mellitus for glycaemic control. Concerns have arisen regarding adverse events caused by this drug, particularly concerning arthralgias. Here, we report on a 56-year-old man being treated with sitaglip...
Kaydedildi:
| Yayımlandı: | BMJ Case Rep |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6720914/ https://ncbi.nlm.nih.gov/pubmed/31444259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2018-228981 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|